List of Excipients in Branded Drug INDOMETHACIN ER

Generic Drugs Containing INDOMETHACIN ER

Company	Ingredient	NDC	Excipient
Apotheca Inc	indomethacin	12634-160	D&C YELLOW NO. 10
Apotheca Inc	indomethacin	12634-160	GELATIN
Apotheca Inc	indomethacin	12634-160	MANNITOL
Apotheca Inc	indomethacin	12634-160	POVIDONE
Apotheca Inc	indomethacin	12634-160	SUCROSE
Apotheca Inc	indomethacin	12634-160	TALC
Apotheca Inc	indomethacin	12634-160	TITANIUM DIOXIDE

What are the Most Frequently-Used Excipients in INDOMETHACIN ER?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10
1	GELATIN
1	MANNITOL
1	POVIDONE
1	SUCROSE
1	TALC
1	TITANIUM DIOXIDE

Last updated: August 5, 2026

Indomethacin extended-release is a mature, genericized NSAID with limited active-ingredient exclusivity but continuing formulation and supply-chain opportunities. The strongest commercial positions are likely to come from differentiated release control, excipient qualification, capsule technology, low-nitrosamine manufacturing, and lifecycle products rather than from new chemical-entity patents. U.S. opportunities center on reliable bioequivalence, robust dissolution performance, and lower-cost production of 75 mg extended-release capsules.

Indomethacin ER Excipient Strategy and Commercial Opportunities

What is the commercial profile of indomethacin extended-release?

Indomethacin is a nonsteroidal anti-inflammatory drug used for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute painful shoulder, and acute gouty arthritis. The extended-release product is generally supplied as a 75 mg capsule and is intended to reduce dosing frequency compared with immediate-release indomethacin products.[1]

The product is commercially mature:

Attribute	Indomethacin ER profile
Active ingredient	Indomethacin
Dosage form	Extended-release oral capsule
Common strength	75 mg
Therapeutic class	NSAID
U.S. regulatory pathway	Generic prescription drug, typically ANDA
Reference product	Indocin SR, where applicable
Molecule exclusivity	Expired
Main competitive factors	Price, supply reliability, bioequivalence, dissolution, manufacturing scale
Primary formulation challenge	Controlling release of a poorly water-soluble, acidic drug
Key clinical limitation	Gastrointestinal, renal, cardiovascular and central nervous system risks associated with indomethacin

Indomethacin has low aqueous solubility and pH-dependent dissolution behavior. These characteristics make the excipient system important for maintaining consistent release across gastric and intestinal conditions. The formulation must also avoid excessive dose dumping, particularly under fed conditions or after exposure to alcohol-containing media.

What excipients are suitable for indomethacin ER?

A commercially practical formulation would typically use a release-controlling polymer, a filler or matrix former, a wetting or dispersion aid, a lubricant, and capsule-shell excipients. The final selection must be supported by FDA inactive-ingredient precedent, product-specific safety limits, and comparative dissolution data.[2]

Hydrophilic matrix excipients

Hydrophilic polymers are a conventional option for extended-release capsules and multiparticulate systems.

Excipient class	Examples	Strategic role
Hypromellose	HPMC grades with varying viscosity	Forms a hydrated gel matrix and controls drug diffusion
Hydroxypropyl cellulose	HPC grades	Matrix formation and granulation aid
Polyethylene oxide	High-molecular-weight PEO	Strong swelling and erosion control
Carbomer	Crosslinked polyacrylic acid	Swelling and release retardation

Hypromellose is commercially attractive because it has broad regulatory familiarity and multiple viscosity grades. A lower-viscosity grade may support processability and moderate release control, while a higher-viscosity grade can reduce burst release. Excessive polymer loading can produce incomplete release or prolonged gastrointestinal residence.

Indomethacin’s acidic character requires testing across multiple pH conditions. A matrix that performs well at intestinal pH may release too slowly in the stomach, while a formulation optimized for acidic media may release too rapidly after entering the intestine.

Hydrophobic and insoluble polymers

Hydrophobic coating systems can provide greater control than a simple hydrophilic matrix.

Potential excipients include ethylcellulose and ammonio methacrylate copolymers. These materials can be applied as coatings to drug-loaded pellets, granules, or mini-tablets. The coating level, pore former, plasticizer, and curing conditions determine release kinetics.

A multiparticulate design has several commercial advantages:

• Reduced sensitivity to local gastrointestinal transit.
• Lower risk that one unit will release the entire dose.
• Greater flexibility in combining immediate-release and extended-release fractions.
• Easier adjustment of release through coating weight gain.
• Potential for capsule filling with pellets rather than a monolithic powder blend.

The disadvantages are higher process complexity, greater equipment requirements, and more demanding control of pellet size, coating uniformity, residual solvent, and capsule fill weight.

Wetting agents and solubility-support excipients

Because indomethacin is poorly water-soluble, wetting and dispersion control may affect both initial release and batch-to-batch reproducibility. Candidate materials include sodium lauryl sulfate, poloxamers, polysorbates, and selected lipid-based excipients.

These materials require careful optimization. A surfactant can improve wetting but also create an undesirable early release spike. It can also change the dissolution profile differently in fed and fasted media. The commercial objective is not maximum dissolution speed. It is reproducible release that matches the reference product over the complete testing period.

Fillers, binders, and process aids

Common supporting excipients may include microcrystalline cellulose, lactose, starches, povidone, colloidal silicon dioxide, and magnesium stearate. Selection should account for:

• Water activity and hygroscopicity.
• Compatibility with indomethacin.
• Powder flow during capsule filling.
• Granule strength.
• Lubrication sensitivity.
• Capsule-shell brittleness.
• Dissolution impact.

Lactose may offer cost and processing advantages but can create compatibility or patient-specific concerns in some formulations. Microcrystalline cellulose can improve flow and compactability but may alter water penetration and release. Magnesium stearate concentration and blending time require control because excessive hydrophobic lubrication can slow wetting and dissolution.

What formulation architectures offer the strongest commercial opportunity?

Polymer-coated multiparticulates

Polymer-coated pellets are the most flexible platform for differentiated indomethacin ER products. The formulator can use a drug-loaded core, seal coat, functional polymer layer, pore former and overcoat. Release can be adjusted without changing the active-ingredient dose.

The main commercial opportunity is process optimization rather than broad composition claims. Potential protectable elements include:

• Narrow pellet-size distribution.
• Specific coating weight gain.
• Defined polymer ratios.
• Controlled curing conditions.
• A dual-population pellet blend.
• A specified dissolution profile across pH conditions.
• Reduced fed-state variability.

Hydrophilic matrix capsules

Matrix-filled capsules are less expensive to manufacture and may be suitable for a cost-focused generic. They are more exposed to variability from powder segregation, fill-weight variation, polymer hydration, and gastrointestinal conditions.

This platform is attractive when the development objective is a straightforward ANDA with limited manufacturing complexity. It is less attractive for premium positioning unless the product demonstrates improved tolerability, lower variability, or a meaningful dosing advantage.

Dual-release systems

A dual-release capsule can combine an immediate-release fraction with an extended-release fraction. This design may improve onset while preserving once-daily or reduced-frequency dosing. The technical risk is greater because both the early and late portions of the dissolution profile must remain within a narrow target.

A dual-release system could support a 505(b)(2) strategy if the sponsor pursues a clinical or labeling difference. The product would face a higher evidence burden than a conventional ANDA and would need a clear clinical or commercial rationale.

Abuse-deterrent or tamper-resistant formats

Abuse deterrence is unlikely to be a primary value driver for indomethacin. The drug is not generally treated as a high-abuse-risk product. Investments in tamper resistance would probably have a weaker return than investments in manufacturing efficiency, capsule stability, or bioequivalence robustness.

What FDA regulatory requirements affect indomethacin ER development?

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug. Extended-release products generally require more extensive testing than immediate-release products because the release mechanism affects exposure over time.[3]

Key development packages include:

1. Comparative dissolution testing across multiple media and time points.
2. Single-dose pharmacokinetic bioequivalence in fasted conditions.
3. Fed-state testing where required by the current FDA product-specific guidance.
4. Evaluation of Cmax, AUC, partial AUC, and terminal exposure parameters.
5. Stability testing in the proposed commercial container-closure system.
6. Capsule-opening and sprinkle testing if the label permits administration with food.
7. Evaluation of alcohol-induced dose dumping where relevant to the release technology.
8. Control of critical material attributes and critical process parameters.

The product’s dissolution method is a major regulatory and commercial asset. A formulation that passes a limited development screen but shows sensitivity to pH, agitation, food, or alcohol can generate costly reformulation and repeat bioequivalence work.

What patents protect indomethacin ER products?

The active ingredient is old, and broad composition-of-matter exclusivity is not available. The relevant intellectual-property position is more likely to involve formulation, manufacturing, delivery, or method-of-use claims.

Formulation patents

Potential formulation claims may cover:

• Specific hydrophilic-polymer concentrations.
• Coated pellets or granules.
• Dual-release dosage forms.
• Multiparticulate capsule populations.
• Defined dissolution ranges.
• Stabilized compositions.
• Reduced food-effect formulations.
• Specific excipient ratios.

Many such claims have limited commercial duration because indomethacin ER products originated decades ago. A new entrant should distinguish between expired legacy patents and any later patents covering a specific product, manufacturing process, or delivery system.

Method-of-use patents

Method-of-use claims may address particular inflammatory conditions, dosing regimens, or patient populations. Their value is limited where generic labeling can rely on a skinny-label strategy and where the protected use is not necessary for the core market.

Orange Book status and Paragraph IV risk

For a currently listed reference product, the Orange Book may identify patents that remain relevant to an ANDA certification.[4] Because indomethacin ER is a mature product, the principal patent risk is likely to arise from product-specific formulation or use claims rather than active-ingredient patents.

A Paragraph IV challenge could target:

• Invalidity of an asserted formulation patent.
• Non-infringement based on a different polymer system.
• Expiration or nonapplicability of a listed patent.
• Lack of patent-listing eligibility.
• Absence of a claim covering the proposed generic formulation.

The commercial risk depends on the number of available manufacturers, the strength of the listed patents, the reference product’s market share, and the timing of settlement or launch. Patent diligence must use current Orange Book listings and federal court records because legacy listings and litigation outcomes change over time.[4,5]

When does indomethacin ER lose exclusivity?

Indomethacin’s core exclusivity has already expired. The commercial question is therefore not loss of molecule exclusivity but the remaining protection around individual extended-release products.

Exclusivity category	Strategic status
New chemical entity exclusivity	Expired
Core composition-of-matter patent	Expired
Generic entry	Established or legally available, subject to product-specific requirements
Formulation patents	Must be reviewed by product and jurisdiction
Regulatory exclusivity	May apply only if a later product received qualifying approval
Trade secrets	May remain relevant for coating, granulation, process control, or supplier qualification

A generic sponsor should not assume that the absence of active ingredient exclusivity eliminates all barriers. The practical barriers are often technical: obtaining a matching release profile, meeting fed-state requirements, controlling capsule fill weight, and maintaining supply at a price that supports a low-margin product.

Which companies are challenging or competing in indomethacin ER?

The competitive field consists primarily of generic manufacturers and contract development and manufacturing organizations rather than innovative biotechnology companies. Typical competitors may include large generic companies, regional suppliers, and authorized generic distributors.

Competition is likely to focus on:

• Reliable API sourcing.
• Low-cost capsule filling.
• Access to qualified release-controlling polymers.
• Avoidance of supply interruptions.
• Regulatory success on the first cycle.
• Wholesaler and hospital-contract access.
• Ability to maintain inventory despite low unit economics.

Indomethacin ER is unlikely to attract biosimilar competition because it is a small-molecule drug, not a biologic. The relevant competitive threat is generic substitution, not biosimilar interchangeability.

What excipient suppliers have commercial opportunities?

Excipient suppliers can create value through platform materials and regulatory support rather than through commodity volume alone.

Higher-value opportunities

• High-purity hypromellose grades with predictable viscosity.
• Ethylcellulose and functional coating systems.
• Ready-to-use aqueous or solvent-based coating dispersions.
• Low-nitrite and low-nitrate excipient grades.
• Excipient systems with strong lot-to-lot dissolution consistency.
• Co-processed fillers that improve capsule-filling performance.
• Technical packages supporting FDA inactive-ingredient review.
• Stability data for moisture-sensitive formulations.
• Global regulatory documentation and supply redundancy.

A supplier that can reduce formulation development time or dissolution variability may obtain stronger pricing than a supplier selling standard-grade lactose or magnesium stearate.

Manufacturing and IP barriers

The most defensible manufacturing know-how may involve:

• Pellet layering.
• Coating uniformity.
• Polymer curing.
• Solvent removal.
• Control of porosity and pore-former distribution.
• Segregation control during capsule filling.
• In-process dissolution testing.
• Scale-up from pilot coating equipment to commercial equipment.

These capabilities can support trade-secret protection even where patent protection is weak. A formulation company may also pursue process patents, but the claims should be narrow enough to distinguish the actual manufacturing advantage and broad enough to cover commercial scale.

How strong is the patent estate for indomethacin ER?

The patent estate is generally weaker than the technical development burden. Broad molecule protection is gone, while formulation claims are likely to be narrow, product-specific, and vulnerable to design-around.

IP category	Relative strength
Active ingredient	Very weak or expired
Basic extended-release concept	Weak because of prior art
Specific polymer matrix	Moderate only if narrowly defined and valid
Multiparticulate coating process	Potentially moderate
Manufacturing know-how	Potentially strong as a trade secret
Method of use	Variable and often label-dependent
Excipient supply position	Strong only with qualification, quality, or capacity advantages

The strongest commercial moat is likely to combine regulatory approval, a reproducible dissolution profile, qualified suppliers, and manufacturing reliability. Patent rights alone are unlikely to support a durable premium.

What generic launch scenarios exist?

Low-cost conventional ANDA

This approach uses a familiar matrix or multiparticulate system, targets the reference product’s profile, and competes on price. It requires limited commercial differentiation and is most exposed to price erosion.

Differentiated extended-release capsule

A sponsor could pursue lower food sensitivity, reduced variability, or a more convenient dosing regimen. The product may justify a higher price only if the FDA label and clinical evidence support a meaningful benefit.

505(b)(2) lifecycle product

A 505(b)(2) strategy could support a new strength, delivery format, or administration method. It may generate greater value but requires more clinical and regulatory investment.

Contract-manufacturing opportunity

A CDMO could offer indomethacin ER development as part of a broader modified-release platform. The opportunity is strongest where the CDMO has fluid-bed coating, multiparticulate handling, analytical dissolution, and commercial capsule-filling capacity.

What is the revenue exposure and market outlook?

Indomethacin ER is generally a low-to-moderate revenue opportunity per product because generic pricing limits gross margin. Revenue can still be attractive when the manufacturer has:

• Low-cost API access.
• High equipment utilization.
• Multiple customer contracts.
• Strong wholesaler distribution.
• Stable supply during competitor shortages.
• A differentiated formulation with limited direct competition.

The principal financial risks are price compression, low prescription volume, reference-product decline, manufacturing deviations, and supply-chain interruptions. A supplier should model margin using realistic generic price erosion rather than assuming branded-NSAID pricing.

Key Takeaways

• Indomethacin ER is a mature small-molecule generic market with expired core exclusivity.
• The primary technical challenge is controlling release of a poorly soluble, pH-dependent NSAID.
• Hypromellose matrices and polymer-coated multiparticulates are the most practical formulation platforms.
• Multiparticulate systems provide more release-control flexibility but require higher manufacturing investment.
• FDA bioequivalence, fed-state performance, dissolution matching, and dose-dumping control are central development requirements.
• Formulation patents may provide limited, narrow protection; manufacturing know-how and regulatory execution are more durable commercial assets.
• Biosimilar risk is not relevant because indomethacin is a small molecule.
• Excipient suppliers have the greatest opportunity in functional polymers, coating systems, low-variability materials, and regulatory support.
• A conventional ANDA is the lowest-risk path; a 505(b)(2) product requires a defensible clinical or administration advantage.
• Commercial success depends more on cost, supply reliability, and bioequivalence than on broad patent exclusivity.

FAQs

Is indomethacin ER a good candidate for a new generic manufacturer?

Yes, if the manufacturer has modified-release development capability and can operate at low unit cost. The product is less attractive for companies without fluid-bed coating, advanced dissolution testing, or reliable API sourcing.

Which excipient is most important in indomethacin ER?

The release-controlling polymer is usually the most influential excipient. Hypromellose, ethylcellulose, and ammonio methacrylate copolymers can materially change dissolution, food sensitivity, and dose-dumping behavior.

Can indomethacin ER be reformulated as a once-daily product?

Potentially, but the sponsor must demonstrate adequate exposure, tolerability, and bioequivalence or clinical justification through the applicable FDA pathway. A once-daily product may require more than a simple excipient substitution.

Does extended-release indomethacin reduce gastrointestinal toxicity?

Not necessarily. Extended release changes exposure and dosing frequency but does not eliminate the gastrointestinal, renal, cardiovascular, or other risks associated with indomethacin and NSAIDs.[1]

Are excipient patents sufficient to block a generic competitor?

Usually not by themselves. A defensible position would require valid claims covering the commercial formulation or process, supported by regulatory and manufacturing advantages that make design-around costly or impractical.

References

1. U.S. Food and Drug Administration. (n.d.). Indomethacin extended-release capsule prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Generic drug development and approval process. https://www.fda.gov/drugs/generic-drugs

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (n.d.). Paragraph IV drug product applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-applications